Please login to the form below

Not currently logged in
Email:
Password:

NICE recommendation

This page shows the latest NICE recommendation news and features for those working in and with pharma, biotech and healthcare.

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

England’s cost-effectiveness watchdog NICE issued a positive recommendation for the drug back in  2018, not long after Crysvita was granted a conditional marketing authorisation from the European Medicines Agency.

Latest news

  • NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

    Lynparza. Also coming out of the NICE appraisal process with a recommendation is AstraZeneca’s  Lynparza (olaparib) for the treatment of adults with relapsed platinum-sensitive BRCA1/BRCA2 mutated ovarian, fallopian ... Xospata was also too costly for

  • Takeda’s HAE drug Takhzyro backed by NICE Takeda’s HAE drug Takhzyro backed by NICE

    Cinryze is approved for prevention, and while Berinert isn’t, NICE says the drug is sometime prescribed off-label for this purpose. ... HAE attacks are unpredictable, painful and debilitating. [The] recommendation from NICE means that people living

  • NICE approves BioMarin’s Brineura after initial setback NICE approves BioMarin’s Brineura after initial setback

    The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... NICE is due to provide a further update on the expected publication date of the Final Evaluation Document soon, which will reveal the full details

  • NICE’s fast-track catapults Skyrizi into market NICE’s fast-track catapults Skyrizi into market

    Watchdog also gives direction on comparing rival treatments. NICE has published a final recommendation for AbbVie and Boehringer Ingelheim’s Skyrizi today, completing a fast-track process which will see the ... The NICE approval means Skyrizi is

  • AbbVie scores FDA approval for arthritis treatment upadacitinib AbbVie scores FDA approval for arthritis treatment upadacitinib

    The Boehringer Ingelheim-partnered psoriasis treatment received a fast-track recommendation from NICE following European marketing approval earlier this year.

More from news
Approximately 2 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • The UK’s new medicines pricing deal – opportunities and risks for pharma The UK’s new medicines pricing deal – opportunities and risks for pharma

    Sciences Council, the NICE Implementation Collaborative (NICE) and the Accelerated Access Collaborative (AAC). ... they see faster uptake in the NHS, they could also leverage that NICE recommendation in other countries too.

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Companies will still need to work hard to win a NICE ‘yes’ recommendation, and may still yet have to accept optimised - as NICE calls them - or restricted - as industry calls them - ... None of the four therapies approved to date under the NICE HST

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision. ... positive recommendation at which point it would move out of the Fund into mainstream

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. ... It sounds like good value and NICE has also said it is,” says Anson.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics